Original ArticleImpact of Fluconazole Prophylaxis on Incidence and Outcome of Invasive Candidiasis in a Neonatal Intensive Care Unit
Section snippets
Methods
WHT is a facility catering to women with uncomplicated and high-risk pregnancies, and more than 8000 deliveries have occurred annually since 1999. WHT has a 40-bed level III and 80-bed level II NICU staffed by 9 full-time neonatologists. In April 2002, a FP protocol based on that used by Kaufman et al4 was initiated in the NICU. Infants were eligible for FP if they were ELBW, aged ≤ 5 days, and did not have “liver failure” (defined as hepatomegaly, jaundice, conjugated hyperbilirubinemia, and
Infants Who Received Fluconazole Prophylaxis
During the FP period, 196 of 240 (82%) ELBW infants admitted to NICU received FP. Nineteen infants with BW ≥ 1000 g also received FP, so a total of 215 infants (median BW 765 g [range 315–1215]; median gestation 26 weeks [range 23–32]) received a median of 16 doses of fluconazole over a median of 32 days. Seventy of 215 (33%) infants completed 6 weeks of FP. Fluconazole was discontinued early in 117 (54%) because intravenous access no longer was needed, 17 (8%) died of unrelated causes, 5
Discussion
The emergence of Candida as a major pathogen in neonates is a phenomenon evolving in tandem with the survival of increasingly preterm and low BW infants.1, 2, 3, 5, 6, 7, 8, 9, 10 Many risk factors associated with the development of IC in these vulnerable infants are unavoidable because they represent the consequence of manipulations attendant to the intensive care required in the first few weeks of life. Like many neonatal conditions, the clinical manifestations of IC are nonspecific, and
References (17)
- et al.
Candida: an increasingly important pathogen in the nursery
Pediatr Clin North Am
(1988) - et al.
Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network
J Pediatr
(1996) - et al.
Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network
Pediatrics
(2002) - et al.
Fluconazole prophylaxis against fungal colonization and infection in preterm infants
N Engl J Med
(2001) - et al.
Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia
Clin Infect Dis
(2001) - et al.
Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases
Pediatr Infect Dis J
(1998) - et al.
Empirical therapy for neonatal candidemia in very low birth weight infants
Pediatrics
(2003) - et al.
Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group
Pediatr Infect Dis J
(2000)
Cited by (105)
Healthcare-Associated Infections
2023, Avery's Diseases of the NewbornTherapeutic drug monitoring for antifungal triazoles: pharmacologic background and current status
2020, Handbook of Analytical SeparationsHealth Care-Associated Infections
2018, Avery's Diseases of the Newborn: Tenth EditionCandiduria: Evidence-based approach to management, are we there yet?
2017, Journal de Mycologie MedicaleCitation Excerpt :The risk factors for community-acquired candiduria differ from nosocomial infection in that the patients in the former group are younger in age, female gender and pregnant and are more likely to experience dysuria [1]. The other patient population at risk for candiduria, are the prematurely born neonates, especially those who receive antibiotics and have indwelling lines [49–53]. Lower incidence of candiduria is observed in pediatric ICUs because of less utilization of urinary catheters as compared to adult ICUs [54].
Health Care-Associated Infections
2017, Avery's Diseases of the Newborn, Tenth EditionIntegrated measures for prevention of invasive Candida infections in preterm infants in a Chinese neonatal intensive care unit
2015, American Journal of Infection Control
Presented in part at the Pediatric Academic Societies' Annual Meeting, May 1-4, 2004, San Francisco, CA (Abstract 2244) and at the Annual Meeting of Infectious Disease Society of America, September 30-October 3, 2004, Boston, MA (Abstract 249).